Summary
Miconazole nitrate was investigated in 169 normal volunteers for its safety and its antifungal action on the bronchial and intestinal flora after oral administration, and for its biotransport and transformation after oral, intravaginal and percutaneous administration. — Oral doses of 3 g a day for nine weeks produced no haematological, biochemical or ECG abnormalities. Within the first week of treatment, miconazole significantly reduced the number of fungal colonies in cultures of sputum and faeces, and inhibited tetracycline-induced fungal overgrowth in the faeces. Oral miconazole significantly improved dermatophytosis. — Miconazole was absorbed moderately well from the gastrointestinal tract and was virtually not absorbed from the mucous membrane and skin.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Godefroi, E.F., Heeres, J., Van Cutsem, J., Janssen, P.A.J: The preparation and antimycotic properties of derivatives of l-phenethylimidazole. J. Med. Chem.12, 784–791 (1969).
Van Cutsem, J., Thienpont, D.: Miconazole, a broad spectrum antimycotic agent with antibacterial activity. Chemotherapy17, 392–404 (1972).
Brugmans, J.P., Van Cutsem, J., Thienpont, D.C.: Treatment of longterm tinea pedis with miconazole. Doubleblind clinical evaluation. Arch. Dermatol.102, 428–432 (1970).
Botter, A.A.: Topical treatment of nail and skin infections with miconazole, a new broad-spectrum antimycotic. Mykosen14, 187–191 (1971).
Botter, A.A.: Further experiences with miconazole nitrate, a broad-spectrum antimycotic with antibacterial activity. Mykosen15, 179–183 (1972).
Vandaele, R., Uyttendaele, K.: Miconazole nitrate in the topical treatment of dermatomycoses. A clinical evaluation Arzneimittel-Forsch.22, 1221–1223 (1972).
Alexander, J., Cornelissen, J., Debrabandere, L., Timmermans, H.L., Vandeputte, E., Van Waes, E., Van Waes-Van de Velde, E.: Miconazole (R 14889) in the treatment of vaginal candidiasis. A multicentric trial in gynecological practice. European J. Obstet. Gynecol.2, 65–70 (1972).
Godts, P., Vermylen, P., Van Cutsem, J.: Clinical evaluation of miconazole nitrate in the treatment of vaginal candidiasis. Arzneimittel-Forsch.21, 256–257 (1971).
Proost, J., Maes-Dockx, F., Nelis, M., Van Custem, J.: Miconazole in the treatment of mycotic vulvovaginitis. Am. J. Obstet. Gynecol.112, 688–692 (1972).
Peeters, F., Snauwaert, R., Segers, J., Van Cutsem, J., Amery, W.: Treatment of candidal vaginitis with miconazole nitrate, a new broad-spectrum antimycotic. Changes in microbiology, vaginal pH and cytology. Arzneimittel-Forsch. (in press).
Thiery, M., Mrozowski, B.J., Van Kets, H.: Miconazole, a new broadspectrum antimycotic, in the treatment of vaginal candidiasis. Mykosen15, 35–37 (1972).
Heykants, J., Brugmans, J., Verhaegen, H.: Difenoxine (R 15403), the active metabolite of diphenoxylate (R 1132). Part 6: Absorption, excretion and metabolism in rats. Arzneimittel-Forsch.22, 529–531 (1972).
Editorials: Candidiasis: Colonization vs infection. J. Amer. Med. Ass.215, 285–286 (1971).
Candida Infections. Med. Letter12, 29–31 (1970).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brugmans, J., Van Cutsem, J., Heykants, J. et al. Systemic antifungal potential, safety, biotransport and transformation of micronazole nitrate. Eur J Clin Pharmacol 5, 93–99 (1972). https://doi.org/10.1007/BF00561752
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00561752